The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
Abstract Objective While PD-L1 expression serves as a predictive biomarker for programmed cell death 1 and its ligand (PD-1/PD-L1) inhibitor efficacy in patients with non-small cell lung cancer (NSCLC), its association with treatment-related adverse events (TRAEs) has yet to be fully elucidated. Thi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14218-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850206367174885376 |
|---|---|
| author | Qian Zhu Hao Hu Li-Ying OuYang Rong Yang Wen-Xiao Wei Pin Huang Xin-Rong He |
| author_facet | Qian Zhu Hao Hu Li-Ying OuYang Rong Yang Wen-Xiao Wei Pin Huang Xin-Rong He |
| author_sort | Qian Zhu |
| collection | DOAJ |
| description | Abstract Objective While PD-L1 expression serves as a predictive biomarker for programmed cell death 1 and its ligand (PD-1/PD-L1) inhibitor efficacy in patients with non-small cell lung cancer (NSCLC), its association with treatment-related adverse events (TRAEs) has yet to be fully elucidated. This study systematically evaluated the correlation between PD-L1 expression status and TRAEs in patients with NSCLC. Methods We systematically searched the Cochrane Library, Embase, and PubMed databases from inception to June 30, 2024, to identify prospective clinical trials examining PD-1/PD-L1 inhibitors among NSCLC patients that reported treatment-related toxicity data stratified by PD-L1 expression. Results Twenty-six prospective trials (N = 5,453) were analyzed. At the 1%, 25%, and 50% PD-L1 cutoffs, PD-L1-negative patients presented significantly reduced risks of grade 3–4 TRAEs (OR = 0.37, 0.53, 0.41; 95% CI = 0.18–0.77, 0.31–0.90, 0.19–0.97; P < 0.01, 0.02, 0.04). Similarly, PD-L1-negative patients had significantly reduced risks of AEs leading to treatment discontinuation at the 1% and 25% PD-L1 cutoffs (OR = 0.25, 0.38; 95% CI = 0.08–0.76, 0.16–0.89; P = 0.01, 0.03) but not at the 50% PD-L1 cutoff (OR 0.28, 95% CI 0.07–1.12, P = 0.07). Subgroup analyses revealed elevated all-grade TRAEs with the 22C3 immunohistochemistry assay (P < 0.001), whereas first-line therapy recipients (P = 0.006) and open-label trial participants (P = 0.002) presented increased grade 3–4 TRAEs. Conclusions PD-L1 positivity may predict increased risks of grade 3–4 TRAEs and AEs leading to treatment discontinuation in NSCLC patients receiving PD-1/PD-L1 blockade. Furthermore, PD-L1 expression might be a useful biomarker for toxicity management in patients with NSCLC after PD-1/PD-L1 inhibitor treatment. |
| format | Article |
| id | doaj-art-cb28a5cfdcce48c19af2812e6cb52e83 |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-cb28a5cfdcce48c19af2812e6cb52e832025-08-20T02:10:50ZengBMCBMC Cancer1471-24072025-04-0125111310.1186/s12885-025-14218-5The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancerQian Zhu0Hao Hu1Li-Ying OuYang2Rong Yang3Wen-Xiao Wei4Pin Huang5Xin-Rong He6State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Radiation Therapy, General Hospital of Southern Theater CommandState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterAbstract Objective While PD-L1 expression serves as a predictive biomarker for programmed cell death 1 and its ligand (PD-1/PD-L1) inhibitor efficacy in patients with non-small cell lung cancer (NSCLC), its association with treatment-related adverse events (TRAEs) has yet to be fully elucidated. This study systematically evaluated the correlation between PD-L1 expression status and TRAEs in patients with NSCLC. Methods We systematically searched the Cochrane Library, Embase, and PubMed databases from inception to June 30, 2024, to identify prospective clinical trials examining PD-1/PD-L1 inhibitors among NSCLC patients that reported treatment-related toxicity data stratified by PD-L1 expression. Results Twenty-six prospective trials (N = 5,453) were analyzed. At the 1%, 25%, and 50% PD-L1 cutoffs, PD-L1-negative patients presented significantly reduced risks of grade 3–4 TRAEs (OR = 0.37, 0.53, 0.41; 95% CI = 0.18–0.77, 0.31–0.90, 0.19–0.97; P < 0.01, 0.02, 0.04). Similarly, PD-L1-negative patients had significantly reduced risks of AEs leading to treatment discontinuation at the 1% and 25% PD-L1 cutoffs (OR = 0.25, 0.38; 95% CI = 0.08–0.76, 0.16–0.89; P = 0.01, 0.03) but not at the 50% PD-L1 cutoff (OR 0.28, 95% CI 0.07–1.12, P = 0.07). Subgroup analyses revealed elevated all-grade TRAEs with the 22C3 immunohistochemistry assay (P < 0.001), whereas first-line therapy recipients (P = 0.006) and open-label trial participants (P = 0.002) presented increased grade 3–4 TRAEs. Conclusions PD-L1 positivity may predict increased risks of grade 3–4 TRAEs and AEs leading to treatment discontinuation in NSCLC patients receiving PD-1/PD-L1 blockade. Furthermore, PD-L1 expression might be a useful biomarker for toxicity management in patients with NSCLC after PD-1/PD-L1 inhibitor treatment.https://doi.org/10.1186/s12885-025-14218-5PD-L1 expressionPD-1/PD-L1 inhibitorToxicity profileNon-small cell lung cancer |
| spellingShingle | Qian Zhu Hao Hu Li-Ying OuYang Rong Yang Wen-Xiao Wei Pin Huang Xin-Rong He The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer BMC Cancer PD-L1 expression PD-1/PD-L1 inhibitor Toxicity profile Non-small cell lung cancer |
| title | The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer |
| title_full | The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer |
| title_fullStr | The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer |
| title_full_unstemmed | The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer |
| title_short | The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer |
| title_sort | association of pd l1 expression status and the pd 1 pd l1 inhibitor related toxicity profile in non small cell lung cancer |
| topic | PD-L1 expression PD-1/PD-L1 inhibitor Toxicity profile Non-small cell lung cancer |
| url | https://doi.org/10.1186/s12885-025-14218-5 |
| work_keys_str_mv | AT qianzhu theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT haohu theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT liyingouyang theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT rongyang theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT wenxiaowei theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT pinhuang theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT xinronghe theassociationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT qianzhu associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT haohu associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT liyingouyang associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT rongyang associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT wenxiaowei associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT pinhuang associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer AT xinronghe associationofpdl1expressionstatusandthepd1pdl1inhibitorrelatedtoxicityprofileinnonsmallcelllungcancer |